openPR Logo
Press release

PD-L1 Biomarker Testing Market Projected to Grow Steadily During 2017-2027

01-17-2018 01:29 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Future Market Insights

PD-L1 Biomarker Testing Market Projected to Grow Steadily

Immunotherapy is one of the most exciting field in the area of cancer research. Immunotherapy has the power to manage immune system, recognize the cancer cell and fight against it. Our immune system has T- cell that fight against diseases, infections including cancer. The cancer cell represents the protein known as PD-L1 protein. The PD-L1 protein binds to the receptor on the T cell. The PD-L1 protein, that is expressed on the cancer cell inactivate the T cell from attacking the cancer cell. The companies are involved in the research and development in the cancer research by inactivating the protein on the cancer cell e.g. the antibody drug candidate blocks the PD-L1 protein on the cancer cell, so that it does not bind to the PD-1 receptor on the T cell. The PD-L1 protein is the important target and mostly studied in cancer research. Governments in developed countries such as the U.S. raise funds for cancer research to aid in the diagnosis and treatment. Clinical trials are also funded by governments to support companies in developing effective therapy for cancer diagnosis and treatment. The companies are advancing research in the field of immunotherapy and is targeting PD-L1/PD-1 pathway to address different immune pathway for cancer research.

The pharmaceutical companies are focusing on development of different receptor ligand interaction for chronic diseases such as cancer, in order to make sure that next-generation drugs be more efficacious. In April 2016, the U.S. Government allocated US$ 5.2 Bn for the National Cancer Institute (NCI), a Federal Government agency, for cancer research and training. The budget increased by 5.3% as compared to the previous year. NCI conducts clinical trials on cancer patients who require repetitive diagnosis to check the prognosis of cancer. The monoclonal antibodies, that blocks the interaction between checkpoint molecules PD-1 on T cells and PD-L1 on cancer cells are into pipeline, clinical trials are on the way ,if approved will act as a driving factor for revenue generation. Research funding from governments and improving reimbursement scenario for cancer therapy would aid the growth of global PD-L1 biomarker testing market.

Request For Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-5897

PD-L1 Biomarker Testing Market: Drivers and Restrains

Major growth drivers in this segment are rise in prevalence of cancer, constantly growing list of cancer biomarkers, increasing discretionary funding for cancer research, increased medicare coverage for cancer diagnosis and treatment, research in the field of cancer immunotherapy, insurance coverage and reimbursement issues and others are some of the factors boosting the PD-L1 biomarker testing market, drug candidates have been designated as orphan drug to gain accelerated approval and it also allows the company to benefit from a seven year marketing exclusivity, if approved for the particular indication. The FDA undertakes accelerated approval process to bring these therapies to the market faster and make them available for patients in need. According to the Organisation for Economic Co-operation and Development (OECD) statistics, the global biomarkers market for companion diagnostics is was valued at US$ 5.2 Bn in 2012 and is expected to rake US$ 8.4 Bn by 2016 Also, strict regulations, need huge investment of time and money, invest in expensive clinical utility studies, and there is no guarantee that the product will get coverage, and others are some of the factors restraining the market growth

PD-L1 Biomarker Testing Market: Segmentation

The global PD-L1 Biomarker Testing market has been classified on the basis of product type, application, end user and geography.

Based on Assay Type, the global PD-L1 biomarker testing market is divided into following:

PD-L1 IHC 22C3 Assay
PD-L1 IHC 28-8 Assay
PD-L1 (SP142) Assay
PD-L1 (SP263) Assay

Based on the disease indication, the global PD-L1 biomarker testing market is divided into following:

Non-Small Cell Lung Cancer (NSCLC)
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Bladder Cancer
Others

Based on the End User, the global PD-L1 Biomarker Testing market is divided into following:

Hospital Associated Labs
Independent Diagnostic Laboratories
Biotechnology and Pharmaceutical Company
Cancer Research Institutes
Others

PD-L1 Biomarker Testing Market: Overview

The PD-L1 Biomarker Testing market is segment based on assay type, disease indication, end-user and geography. Based on the product type, PD-L1 biomarker testing market is segmented on the basis of PD-L1 IHC 22C3 Assay, PD-L1 IHC 28-8 Assay, PD-L1 (SP142) Assay, PD-L1 (SP263) Assay and others. Maximizing market penetration on install base, strategic partnerships to enhance consumer base are some of the factors expected to drive the growth of the market. Based on the disease indication segment, the PD-L1 Biomarker Testing market is sub-segmented on the basis of Non-Small Cell Lung Cancer (NSCLC), Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma, Bladder Cancer and others. On the basis on end user, the PD-L1 Biomarker Testing market is segmented on the basis of hospital associated laboratory, independent diagnostic laboratories, biotechnology and pharmaceutical companies, cancer research institutes and others

Request For Report Table of Content (TOC): https://www.futuremarketinsights.com/toc/rep-gb-5897

PD-L1 Biomarker Testing Market: Regional Overview

Region wise, the global PD-L1 Biomarker Testing market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is estimated to account for major share due to increased awareness and technological advancements in the U.S., demand for new and advanced diagnostic equipment’s, Kits and others, government initiatives and funding for production of cost-effective monoclonal antibodies in the U.S. Europe is expected to account for second largest market share due to easy approval procedure for diagnostic tests, Significant increase in cancer diagnosis rates in primary care settings in U.K. Germany, France and other European countries. Significant economic development has led to an increase in healthcare availability in Asia Pacific region providing an opportunity for companies to penetrate Asia Pacific regions. Rising investment in cancer research by government is driving market growth, rise in cancer awareness are some if the factors driving growth in Asia Pacific region

PD-L1 Biomarker Testing Market: Key Players

Some of the key players in global PD-L1 Biomarker Testing market are Agilent Technologies, Inc., Eli Lilly and Company, AstraZeneca, Ventana Medical Systems, Inc. Genentech Inc., Bristol-Myers Squibb, Merck & Co., Inc., Pfizer Inc. and others

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
Abhishek Bhudoliya
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: http://www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release PD-L1 Biomarker Testing Market Projected to Grow Steadily During 2017-2027 here

News-ID: 904895 • Views: 98

More Releases from Future Market Insights

How Changing Dynamics of Cable Testing Market are Reflecting on Growth Strategie …
Global Cable Testing Market: Introduction The cost of the substitution of cables that are concealed is very high. Faults in the cable, bending, kinking, and crushing, are not always visible, which has created the requirement for cable testing. Thus, cable testing helps check the cable functionality, cable quality, and cable conformity. Several times, cable testing by visual inspection is an effective way of identifying the actual problem before it causes any
How Transformative Trends in Self-Organising Network Market are Molding Strategi …
Self-Organising Network: Introduction With accelerated advancements and increasing complexities in the radio network technologies, such as those utilised for the development of LTE and 5G networks, which are used for planning, management, configuration, healing and optimisation, are required to be automated to facilitate efficiency. At present, suppliers are offering self-organising networks that possess the ability to offer optimum performance. Self-organising networks are use cases that perform network governance, including network planning,
Mining Vehicle AC Kits Market: Exploring the Impact of Trends on Strategies of K …
Mining Vehicle AC Kits Market: Introduction Cabin space in mining equipment has become more sophisticated in the recent past. The installation of mining vehicle AC kits has evolved from an optional feature to a necessary feature. Mining equipment manufacturers have made advancements in technology related to efficiency, performance and cost of air conditioning systems in order to make them affordable and economical to enable low-budget and compact installations without compromising on
Key Factors to Fuel Growth of the Talent Acquisition & Staffing Technology and S …
With the growing importance of recruiting and retaining top talent effectively and efficiently, smart hiring processes are the need of the hour. It is about time organisations move beyond merely scrutinising resumes. Salaries and benefits are important factors, but adopting ways that would make candidates an important part of the hiring process will attract the best talent. Studies reveal that due to discrepancies in existing Applicant Tracking Systems (ATS), hiring

All 5 Releases


More Releases for Biomarker

Global Genomic Biomarker Market Research and Forecast 2018-2023
Global genomic biomarkers market size, share, market intelligence, market trends, research and analysis report by disease indication (oncology, cardiology, neurology) by end users (hospitals, diagnostic and research laboratories) forecast 2018-2023 According to the OMR analysis, the global genomic biomarker market is growing at a moderate rate during 2018-2023. The global genomic biomarker market has witnessed a moderate growth due to increasing cases of chronic diseases and rising healthcare expenditure. The global
Key Findings of the Global Biomarker Market
A new business intelligence report released by HTF MI with title “Global Biomarker Market Size, Status and Forecast 2025” that targets and provides comprehensive market analysis with future prospects to 2023. The analysts of the study have garnered extensive research methodologies and data sources (i.e Secondary & Primary Sources) in order to generate collective and useful information that delivers latest market undercurrents and industry trends. Request Sample Report @: https://www.htfmarketreport.com/sample-report/1222502-global-biomarker-market-1 If
Global Cancer Biomarker Market Strategies and Forecast 2025
Qyresearchreports include new market research report "Global Cancer Biomarker Market Size,Status and Forecast 2025" to its huge collection of research reports. QYResearchReports.com has added a new report covering the global Cancer Biomarker market to its vast database. The research report studies the global Cancer Biomarker market to analyze the factors impacting it. The report has been divided into several chapters that discuss the global Cancer Biomarker market in absolute detail. The
Global Cancer Biomarker Market Advantages & Developments 2025
Qyresearchreports include new market research report "Global Cancer Biomarker Market Size,Status and Forecast 2025" to its huge collection of research reports. The global Cancer Biomarker market has been exclusively and elaborately examined in this report while taking into account some of the most pivotal factors holding the capability to influence growth. For the said forecast tenure, the report has shed light on critical market dynamics, which include trends, opportunities, restraints, and
Biomarker Technologies Market : Analysis & Trends 2025
A biomarker also known as biological marker is a gene, molecule or characteristic by which biological state of the body is measured in order to assess and predict a particular disease or some other physiological state of an individual. It helps clinicians in disease identification and effectively plan treatment process. Biomarkers are extensively applied for diagnosis and clinical decision making in various medical specialties including cancer, diabetes, cardiovascular and neurological
Multiplex Biomarker Imaging Market Outlook Report 2027
The global multiplex biomarker imaging market is estimated to be valued at US$ 270 Mn in the year 2017 and is estimated to touch a value of US$ 843 Mn in the year 2027, exhibiting a CAGR of 12% during the period of assessment (2017-2027). Request for TOC @ https://www.futuremarketinsights.com/reports/multiplex-biomarker-imaging-market/toc Increased spending on cancer diagnostic and monitoring Growing incidence of cancer is resulting in increased spending by governments in various countries globally. Complications arising